Every 10-Q that Sunshine Biopharma Inc (SBFM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SBFM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBFM filings page.
Sunshine Biopharma Inc., a Colorado-based pharmaceutical company with generic and OTC operations in Canada and proprietary oncology/antiviral programs, reported second-quarter 2026 results. Q2 2026 revenue was $9,263,687, slightly below $9,410,230 a year earlier, as terminated distribution agreements reduced sales. Gross profit for the quarter was $2,426,682, and the company recorded a net loss of $1,564,048 ($1.15 per share).
For the first six months of 2026, revenue totaled $17,352,452 versus $18,311,571 in 2025, with a net loss of $2,807,917 ($2.95 per share). Operating expenses declined year over year, helped by the absence of a prior-period intangible impairment and lower consulting and R&D costs, partly offset by higher legal fees. Cash and cash equivalents were $13,748,301 at June 30, 2026, and total assets were $33,632,901.
Financing activities in the first half of 2026 provided $7,804,185 of cash, including a May 19, 2026 public offering of 1,200,000 units and warrant exercises. Subsequent to quarter-end, the company established a $4,000,000 at-the-market offering and raised $1,722,555 in net proceeds, received a U.S. patent for its coronavirus protease inhibitors, and continued development of its K1.1 mRNA liver cancer and SBFM-PL4 antiviral candidates.
Sunshine Biopharma reported Q1 2026 sales of $8.1 million, down about 9% from $8.9 million a year earlier, mainly due to the termination of certain distribution agreements. Gross profit was $2.2 million with a margin of 27%, versus $2.7 million and 30.7% in Q1 2025.
The company posted a net loss of $1.24 million, slightly wider than the prior-year loss of $1.18 million, or $(0.25) per share on 4.9 million weighted-average shares. Operating expenses fell to $3.6 million from $4.0 million as accounting, consulting, marketing, office and R&D costs declined, partly offset by higher salaries and legal fees.
Cash and equivalents were $6.9 million at March 31, 2026, with total assets of $27.9 million and no debt beyond lease liabilities. Management estimates current cash and operating cash flows can fund the business for about 17 months while it works to grow Nora Pharma’s Canadian generic drug sales and advance two proprietary programs in liver cancer mRNA and a PLpro inhibitor for SARS coronavirus infections.
Sunshine Biopharma (SBFM) filed its Q3 2025 10‑Q, highlighting year‑over‑year revenue growth and a smaller quarterly loss. Revenue for the quarter reached $9,417,179, up 11.6% from a year ago, with gross profit of $3,073,540. Operating loss was $1,086,613, and net loss narrowed to $883,820, or $0.19 per share.
For the nine months ended September 30, 2025, revenue was $27,728,750 (up 9.7%). Net loss for the period was $3,834,425, reflecting higher G&A and a $1,616,459 impairment of intangible assets tied to product licenses that could not be commercialized. Cash and equivalents were $9,306,438 as of September 30, 2025.
The company completed an April 2025 registered direct offering, receiving $1,828,596 in net proceeds, and reported additional cash from warrant exercises during the year. Shares outstanding were 4,555,945 as of September 30, 2025, and 4,905,945 as of November 13, 2025. Management aims to reduce cost of goods sold toward 60% to move toward breakeven while continuing to expand Nora Pharma’s Canadian generic portfolio.